Source comparison
Comparison: Melanotan II vs Afamelanotide in Vitiligo Research Context
Afamelanotide ([Nle⁴,D-Phe⁷]-α-MSH, NDP-α-MSH) is an MC1R-selective agonist delivered as a subcutaneous biodegradable implant, currently licensed for erythropoietic protoporphyria (EPP) photoprotection. Its MC1R selectivity (Ki ~0.1 nM MC1R; substantially lowe
This comparison does not assign a generated winner or score.
- Afamelanotide ([Nle⁴,D-Phe⁷]-α-MSH, NDP-α-MSH) is an MC1R-selective agonist delivered as a subcutaneous biodegradable implant, currently licensed for erythropoietic protoporphyria (EPP) photoprotection. Its MC1R selectivity (Ki ~0.1 nM MC1R; substantially lower affinity at MC3R/MC4R) is advantageous for melanocyte-targeted research, minimising CNS melanocortin effects. Published clinical data include a randomised trial showing afamelanotide + narrowband UVB combination versus NB-UVB alone, with significantly greater and faster repigmentation at 24 weeks in non-segmental vitiligo (Lim et al., JAMA Dermatology 2015).
- Melanotan II shares the same core pharmacophore but has broader receptor engagement (MC1R + MC3R + MC4R + MC5R). For vitiligo mechanistic research, this non-selectivity is a study design consideration: CNS (appetite suppression, sexual arousal via MC4R/MC3R) and peripheral (exocrine via MC5R) effects must be separated from melanocyte-specific endpoints. Conversely, Melanotan II’s broader anti-inflammatory reach across MC3R/MC4R on immune cells may offer a more comprehensive immunomodulatory profile relevant to the autoimmune component.
- 🔗 Related Reading: For a comprehensive overview of Melanotan 2 pharmacology, mechanisms, UK sourcing, and photoprotection research, see our Melanotan 2 UK Complete Research Guide 2026.
- 🔗 Related Reading: For a broader overview of peptides investigated in dermatological and skin research, see our Best Peptides for Skin Research UK 2026 hub.